



19 March 2024

ASX Announcement

Island Pharmaceuticals announces results of fully underwritten rights issue

MELBOURNE Australia, 19 March 2024: Australian antiviral drug development company, Island Pharmaceuticals Ltd (**ASX: ILA, Island or the Company**) is pleased to announce the results of its fully underwritten, non-renounceable rights issue to Eligible Shareholders as announced to ASX on Monday, 26 February 2024 (**Offer**).

Results of Offer

The fully underwritten Offer will raise approximately \$1.95 million (before costs) and has the potential to raise further funds through the exercise of attaching options, plus Piggy Back Options as outlined in the Prospectus (ASX: 26 February 2024). The Offer provided existing shareholders with the opportunity to subscribe for 2 New Shares for every 5 existing shares held in the Company.

Island CEO and Managing Director, Dr David Foster commented, *“We are very pleased to have had strong support for this Offer, enabling it to be fully underwritten. Thanks goes to all those shareholders that participated in the Rights Offer and to the new investors that supported through sub-underwriting. With this new capital, we are well financed to progress our immediate clinical goals for our lead asset, ISLA-101.”*

ISLA-101 is a well-known drug candidate being repurposed for the prevention and treatment of dengue and other mosquito (or vector) borne diseases.

Funds raised will be used to analyse the Phase 1 dose and prepare for the planned Phase 2 clinical trial (PEACH study). If the options issued under the Offer are exercised, those funds will advance Island’s Phase 2 efficacy study for ISLA-101 in dengue fever, which will define an exciting and critical period for the Company.

The Entitlement Offer was well supported by existing shareholders and all Directors on the Board of Island Pharmaceuticals, with the Company accepting applications for approximately 8.92 million New Shares (accompanied by approximately 8.92 million New Options) at the Issue Price of \$0.06 per New Share (including after allocation of Entitlements under the Rights Issue Offer and the issue of Additional Securities under the Top-Up Facility.)



Approximately 23.58 million remaining New Shares (accompanied by approximately 23.58 million New Options) under the Offer which have not been subscribed by Eligible Shareholders will form part of the Shortfall to be placed by underwriter, PAC Partners Securities Pty Limited, in accordance with the terms of the Underwriting Agreement.

Subject to settlement of funds, the New Shares (and accompanying New Options) subscribed for under the Offer are expected to be issued on Thursday, 21 March 2024, with normal trading of the New Shares expected to commence on Friday, 22 March 2024.

Announcement terms

Capitalised terms used in this announcement but not defined have the meaning given to them in the Prospectus relating to the Offer lodged by the Company with ASX on Monday, 26 February 2024 and dispatched to Eligible Shareholders on Tuesday, 5 March 2024.

--ends--

The release of this announcement was authorised by the Board.

For further information, please contact:

Dr Paul MacLeman
Executive Chairman
Island Pharmaceuticals Ltd
info@islandpharmaceuticals.com

Investors and media, for further information, please contact:

Jane Lowe
IR Department
Mobile: +61 411 117 774
jane.lowe@irdepartment.com.au

About Island Pharmaceuticals

Island (ASX: ILA) is a drug repurposing company, focused on areas of unmet need for antiviral therapeutics to address infectious diseases. Our lead asset is ISLA-101, a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue² fever and other mosquito (or vector) borne diseases.

If ISLA-101 achieves FDA approval, and certain other criteria are met, Island may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval.



This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) could permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit www.islandpharmaceuticals.com for more on Island.